Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.
ACS Medicinal Chemistry Letters June 12, 2025 DOI: 10.1021/acsmedchemlett.5c00265 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | DMT 5-MeO-DMT |
| Topics | 5-MeO-DMT Depression DMT Psychedelic-assisted therapy |
| Keywords | Entheogenic treatment Hallucinogen-assisted therapy Novel drug delivery Injectable drugs Nasal sprays Drug administration Mental health therapy Antidepressant therapy Quick-onset medications Short-duration effects Acute interventions |
| Citations | 1 |
| Key findings | Parenteral and intranasal formulations of DMT and 5-MeO-DMT overcome bioavailability and metabolism limitations, enabling rapid-onset, short-duration therapeutic effects for conditions like treatment-resistant depression. |
Abstract
Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric conditions such as treatment-resistant depression while optimizing tolerability, scalability, and clinical utility.